1,24,25-三羟基维他命 D3 | 50648-94-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 1,24,25-三羟基维他命 D3
• 中文别名: 1,24,25-三羟基维他命D3；(3S,5Z,7E)-9,10-裂胆甾-5,7,10-三烯-1,3,24,25-四醇
• 英文名称: 1,24,25-Trihydroxyvitamin D3
• 英文别名: 1,24,25-trihydroxycholecalciferol；1,24,25-Trihydroxy-cholecalciferol；(1R,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-5,6-dihydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
• CAS: 50648-94-7
• 化学式: C₂₇H₄₄O₄
• 分子量: 432.644
• InChiKey: WFZKUWGUJVKMHC-ZAXLSTGFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  80.9
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• Stabilized pharmaceutical compositions containing derivatives of vitamins D2 and D3
  申请人：TEVA PHARMACEUTICAL INDUSTRIES, LTD.

  公开号：EP0588539A1

  公开（公告）日：1994-03-23

  1. A solid state pharmaceutical composition which comprises at least ingredients (a), (b) and (c) of the following ingredients (a), (b), (c) and (d), namely: (a) at least one active component selected from pharmaceutically active derivatives of vitamin D2 and vitamin D3; (b) at least one pharmaceutically acceptable antioxidant; (c) at least one pharmaceutically acceptable polyoxyalkyl stabilizer; (d) at least one solid pharmaceutical excipient or carrier in an amount sufficient to impart the characteristics of a solid to the composition.

  1.一种固态药物组合物，它至少包含以下成分（a）、（b）、（c）和（d），即： 1： (a) 至少一种活性成分，选自维生素 D2 和维生素 D3 的药学活性衍生物； (b) 至少一种药学上可接受的抗氧化剂； (c) 至少一种药学上可接受的聚氧烷基稳定剂； (d) 至少一种固体药用赋形剂或载体，其用量足以使组合物具有固体的特性。
• Body cavity foams
  申请人：Friedman Doron

  公开号：US20050271598A1

  公开（公告）日：2005-12-08

  The invention relates to an alcohol-free cosmetic or therapeutic foam carrier comprising water, a hydrophobic organic carrier, a foam adjuvant agent, a surface-active agent and a gelling agent. The cosmetic or therapeutic foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble therapeutic and cosmetic agents.

  本发明涉及一种不含酒精的化妆品或治疗泡沫载体，由水、疏水性有机载体、泡沫佐剂、表面活性剂和胶凝剂组成。该化妆品或治疗用泡沫载体不含脂肪醇，因此无刺激性且不干燥。这种不含酒精的泡沫载体适合加入水溶性和油溶性治疗剂和化妆品。
• Steroid kit and foamable composition and uses thereof
  申请人：Friedman Doron

  公开号：US20060018937A1

  公开（公告）日：2006-01-26

  A composition and therapeutic kit including an aerosol packaging assembly including a container accommodating a pressurized product and an outlet capable of releasing a foamable composition, including a steroid as a foam. The pressurized product includes a foamable composition including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam; wherein the pressurized product comprises a foamable composition including: i. a steroid; ii. at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight; iii. a surface-active agent; iv. about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; v. water; and vi. liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition. The composition further may include a therapeutically active foam adjuvant, selected from the group consisting of a fatty alcohol, a fatty acid, a hydroxyl fatty acid; and mixtures thereof.

  一种组合物和治疗包，包括一个气雾剂包装组件，其中包括一个容纳加压产品的容器和一个能够以泡沫形式释放可发泡组合物（包括类固醇）的出口。加压产品包括可发泡组合物，其中可发泡组合物包括：容纳加压产品的容器；以及能够将加压产品作为泡沫释放的出口；其中加压产品包括可发泡组合物，其中可发泡组合物包括： i. 类固醇； ii. 至少一种有机载体，选自由疏水性有机载体、极性溶剂、润肤剂及其混合物组成的组，浓度为约 2%至约 50%（按重量计）； iii.约 0.01%至约 5%（按重量计）的至少一种聚合物添加剂，该聚合物添加剂选 自生物粘合剂、胶凝剂、成膜剂和相变剂组成的组； v. 水；以及 vi. 液化或压缩气体推进剂，其浓度约为总组合物的 3%至约 25%（按重量计）。该组合物还可包括一种治疗活性泡沫佐剂，选自脂肪醇、脂肪酸、羟基脂肪酸及其混合物组成的组。
• Vitamin D3 derivatives
  申请人：TAISHO PHARMACEUTICAL CO. LTD

  公开号：EP0171990B1

  公开（公告）日：1987-11-04
• Foamable vehicle and pharmaceutical compositions thereof
  申请人：Tamarkin Dov

  公开号：US20060275218A1

  公开（公告）日：2006-12-07

  A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.